Dr Themis Charalampous
Sequencing Lead
Themis completed her PhD in molecular microbiology at the University of East Anglia during which she developed a novel metagenomics pipeline using nanopore sequencing technology. The pipeline allowed rapid microbial identification and detection of resistant genes directly from clinical samples.
At her first postdoc at Kings College London, she evaluated and led the implementation of clinical metagenomic sequencing for the rapid diagnosis of respiratory infections in ICU patients which guided early antimicrobial treatment decisions directly influencing patient management. Then, as a KCL research fellow, she led the evaluation and implementation of sequencing-based workflows using nanopore technology.
In her current role at Bactobio, Themis is part of the microbial generation team. She is driving the company’s sequencing workflows and efforts to expand sequencing capabilities.
During her free time, Themis enjoys working out, reading Greek novels, watching Netflix & relaxing.
Dr Themis Charalampous
Sequencing Lead
Themis completed her PhD in molecular microbiology at the University of East Anglia during which she developed a novel metagenomics pipeline using nanopore sequencing technology. The pipeline allowed rapid microbial identification and detection of resistant genes directly from clinical samples.
At her first postdoc at Kings College London, she evaluated and led the implementation of clinical metagenomic sequencing for the rapid diagnosis of respiratory infections in ICU patients which guided early antimicrobial treatment decisions directly influencing patient management. Then, as a KCL research fellow, she led the evaluation and implementation of sequencing-based workflows using nanopore technology.
In her current role at Bactobio, Themis is part of the microbial generation team. She is driving the company’s sequencing workflows and efforts to expand sequencing capabilities.
During her free time, Themis enjoys working out, reading Greek novels, watching Netflix & relaxing.